Intuitive Surgical Faces Pressure Despite Earnings Beat on Muted Guidance

What happened

Intuitive Surgical delivered a strong second quarter with revenue of $2.89 billion (up 19% year-over-year) and adjusted earnings per share of $2.80, surpassing Wall Street estimates of $2.82 billion and $2.51 respectively. Worldwide procedures across the da Vinci and Ion platforms increased approximately 16% year-over-year, with da Vinci procedures growing around 15% and Ion procedures rising 36%. The company placed 468 da Vinci surgical systems during the quarter, up from 395 a year earlier, including 246 of its newer da Vinci 5 systems. The installed base of da Vinci systems grew 12% to 11,710 units. However, US procedure growth slowed to 12% in Q2 from 14% in Q1. Management attributed this deceleration to deferred treatments and changes in patient insurance coverage following the expiration of enhanced Affordable Care Act premium subsidies. Additionally, US da Vinci bariatric cases declined in the high single digits during the quarter due to rising GLP-1 medication usage. For the full year, Intuitive maintained its forecast for worldwide da Vinci procedure growth of 13.5% to 15.5% but indicated results would track closer to the 14.5% midpoint, below analyst expectations of roughly 15.3%. The company reaffirmed its non-GAAP gross profit margin guidance of 68% to 69% of revenue, including an estimated 1% impact from tariffs, and projected non-GAAP operating expense growth of 11% to 13% for the year. Intuitive ended the quarter with $8.63 billion in cash, cash equivalents and investments, up $650 million from the prior quarter, and repurchased approximately 0.9 million shares for $380 million.

Why it matters

The slower US procedure growth and conservative full-year guidance signal potential headwinds to Intuitive Surgical's near-term revenue momentum, particularly in its high-margin instruments and accessories segment, which relies on procedure volumes. The expiration of enhanced Affordable Care Act premium subsidies may lead to higher insurance costs or reduced coverage for some patients, potentially causing delays in elective surgeries performed with da Vinci systems. Additionally, the rising adoption of GLP-1 medications as an alternative to bariatric surgery directly impacts demand for certain da Vinci procedures. These factors introduce uncertainty around procedure-driven instrument demand, which historically has been a key growth driver for the company. The expected 1% revenue impact from tariffs on gross margins also adds to near-term margin pressure. Following the earnings report, multiple Wall Street firms lowered their price targets, with Citi cutting to $500, JPMorgan to $450, and Mizuho to $400, though most maintained 'Buy' or 'Outperform' ratings. The consensus price target of approximately $558 still implies meaningful upside, suggesting analysts view current levels as a potential buying opportunity despite near-term headwinds.

Bigger picture

Intuitive Surgical's results reflect broader pressures facing medical device companies reliant on elective procedure volumes. The expiration of enhanced ACA subsidies represents a structural shift in healthcare coverage that could affect not only Intuitive but also peers in the surgical and procedural device space. Meanwhile, the rapid adoption of GLP-1 medications for weight management is disrupting the bariatric surgery market, a trend with implications for other procedure-based medical technology companies. Intuitive's continued system placements and installed base growth-12% year-over-year for da Vinci and 21% for Ion-demonstrate ongoing hospital adoption of robotic surgery platforms, a positive signal for the long-term expansion of minimally invasive surgery. However, the company's conservative posture on US procedure growth suggests caution around the pace of volume recovery in a shifting healthcare reimbursement environment. The 1% tariff impact on margins also reflects broader trade policy uncertainties affecting the medtech sector. Despite near-term volatility, Intuitive's strong quarterly profitability-with profit up nearly 28%-and robust balance sheet position it to navigate these headwinds, though investors are recalibrating expectations for growth acceleration.

What to watch

Investors should monitor US da Vinci procedure growth trends in the coming quarters to assess whether the slowdown from 14% to 12% stabilizes or accelerates further. Updates on the impact of ACA subsidy expirations on patient coverage and elective surgery volumes will be critical, as will any commentary on efforts to mitigate bariatric procedure declines from GLP-1 adoption. The company's ability to maintain its gross margin guidance of 68% to 69% despite tariff headwinds will signal pricing power and operational efficiency. System placement trends, particularly for the newer da Vinci 5 platform, will provide insight into hospital capital spending and adoption rates. Additionally, any changes to full-year procedure growth guidance-currently centered at 14.5%-could drive further valuation adjustments. Broader healthcare policy developments, including potential changes to ACA subsidies or insurance coverage, will also influence investor sentiment around procedure-based medtech stocks.